BRÈVE

sur ABIONYX (EPA:ABNX)

ABIONYX announces a capital increase without preferential subscription rights

Graphique de l'évolution du cours de l'action ABIONYX (EPA:ABNX).

ABIONYX Pharma is launching a capital increase of approximately 3.4 million euros through the issue of shares accompanied by share subscription warrants (ABSA). The subscription price is set at 1.37 euros per ABSA. Each subscription warrant allows you to obtain one share to be issued at a price of 3 euros. The exercise period is three years.

This operation aims to strengthen the company's cash flow to support its development in sepsis and in the United States. ORSAY 53 has committed to subscribing to nearly 94% of the issue. A historic shareholder, Mr. Luc Demarre, also declared his intention to subscribe.

The Board of Directors of ABIONYX decided to issue 2,472,000 new securities, representing approximately 7.62% of the capital. The new shares will be admitted to trading on Euronext.

R. P.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de ABIONYX